Current Clinical Trials | ECHO Associates

A Beacon of Light on Your Cancer Care Journey

EASTERN CONNECTICUT HEMATOLOGY & ONCOLOGY ASSOCIATES

Current Trials

Genetic Risk Assessment

ECHO Open to Accrual Clinical Trials

Updated: 02/16/2024

Bladder / Urothelial

IMMU-132-06
A Phase II Open-Label study of IMMU-132 in Metastatic Urothelial Cancer after failure of Platinum-Based regimen or Anti-PD-1/PD-L1 based Immunotherapy

Breast

GS-US-592-6173 / Ascent-04
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s choice and Pembrolizumab in Patients with Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, whose Tumors Express PD-L1

GS-US-592-6238 / Ascent-03
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients with Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated with Anti-PD(L)1 Agents in the Early Setting Whose Tumors do Express PD-L1

ML43171
A Phase III, randomized, Open-Label, multicenter study evaluating the efficacy and safety of Giredestrant plus Everolimus compared with Exemestane plus Everolimus in patients with estrogen receptor-positive, HER2-Negative, locally advanced or Metastatic Breast Cancer

WO43919 / INAVO121
A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the efficacy and safety of Inavolisib plus Fulvestrant versus Alpelisib plus Fulvestrant in patients with Hormone Receptor Positive, HER-2-Negative, PIK3CA mutated, locally advanced or Metastatic Breast Cancer who progressed during or after CDK4/6 Inhibitor and Endocrine combination therapy

Colorectal

Metastatic


WO42758 / INTRINSIC
A Phase I/Ib Global, Multicenter, Open-Label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients with Metastatic Colorectal Cancer (INTRINSIC)

Lung

HLX10-020-SCLC302
A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC)

JZP 712-402
Emerge 402: Phase IV Observational Study to Collect Safety and Outcome data in Real-World Setting in Adult Patients with Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca

First Line Metastatic

GS-US-626-6216 / Star-121
A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy versus Pembrolizumab with Chemotherapy for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with no Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations

Mirati 849-007
A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced non-Small Cell Lung Cancer with KRAS G12C Mutation

Xencor XmAb717-06
 A Phase 1b/2, Open-label, Randomized Study of Vudalimab in Combination with Chemotherapy of Pembrolizumab in Combination with Chemotherapy as First-line Treatment in Patients with Advanced Non-small Cell lung Cancer


Lymphoma

LOXO-BTK-20030  *Screening of treatment naïve patients is closed*
A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) versus Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)

Solid Tumors

REC-4881-221
A Phase 2, Open Label Study of REC-4881 in Participants with Unresectable Locally Advanced or Metastatic Cancer with AXIN1 or APC Mutation
 
SGNDV-005
A Phase II Basket Study of Disitamab Vedotin in Adult Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors that Express HER2

Supportive Care

FRNM-008 (Freenome) (Liver, Lung, Ovarian, Gastric and Uterine opened)
A Case Control Study for the Development of Multiomics Blood Test for Cancer Screening

LP-CT-PALO-202101
A randomized, Double-Blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Palonosetron HCl Buccal Film versus IV Palonosetron 0.25 mg for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Moderately Emetogenic Chemotherapy


For more information on clinical trials, please contact Dr. Susan Johnson, Director of Research sjohnson@echoct.com or 860-886-8362.  

To learn about phases of trials and what it means to participate, click here.